Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Janux Therapeutics Inc JANX

Healthcare Biotechnology
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.


NDAQ:JANX - Post by User

Janux Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(274)
•••
Post by whytestockson Feb 27, 2024 10:45am
36 Views
Post# 35901324

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers

Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers
News; $JANX Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday | BenzingaU.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.Shares of Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) ...JANX - Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday | Benzinga


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities